Proteolysis-Targeting Chimeras——A Novel Strategy for Targeted Therapy in Osteosarcoma
10.13865/j.cnki.cjbmb.2025.07.1156
- VernacularTitle:蛋白质水解靶向嵌合体——骨肉瘤靶向治疗的新策略
- Author:
Yu-Yang LI
1
;
Ren-Shuai ZHANG
;
Jing-Rui LI
Author Information
1. 齐鲁医药学院医学检验学院病原生物学与免疫学教研室
- Publication Type:Journal Article
- Keywords:
proteolysis-targeting chimera(PROTAC);
osteosarcoma(OS);
bromodomain and extra-terminal domain(BET);
cellular-mesenchymal epithelial transition factor(C-Met)
- From:
Chinese Journal of Biochemistry and Molecular Biology
2025;41(9):1243-1245
- CountryChina
- Language:Chinese
-
Abstract:
Osteosarcoma is a highly aggressive primary bone tumor that predominantly affects children and adolescents.Conventional treatment modalities are often hindered by issues such as high recurrence rates and the development of drug resistance.Proteolysis-Targeting Chimeras(PROTACs)represent an innovative therapeutic strategy for osteosarcoma,which are designed to selectively degrade pathogenic proteins.This article offers a comprehensive analysis of the mechanisms underlying PROTACs,their tar-geted applications in osteosarcoma—including bromodomain and ultra-terminal domain targeting—and the associated challenges,such as delivery efficiency and off-target toxicity.Additionally,it suggests optimi-zation strategies for bone-targeted delivery(such as using DNA nanoflowers as carriers)and combination therapies(like targeted therapy and chemotherapy),informed by recent research findings,thereby provi-ding a theoretical framework for clinical translation.
